HALISTER: Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760

Gilead’s New Hepatitis C Drug Approved by FDA, Priced at $74,760

Alert: HALISTER
Source: BN (Bloomberg News)

Tickers
GILD US (Gilead Sciences Inc)
ABBV US (AbbVie Inc)
MRK US (Merck & Co Inc)

People
John Milligan (Gilead Sciences Inc)

Topics
BGOV Health Care

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283